| Outcome Measures: |
Primary: Change in CAVI, Change in CAVI at 24 weeks after initiation of protocol treatment compared to baseline, 24 weeks | Secondary: Change in UACR, Proportional changes in geometric mean of UACR at 12 and 24 weeks post-protocol treatment compared to baseline (key secondary endpoint), 12 weeks, 24 weeks|Change in pentosidine, Proportional changes in geometric mean of pentosidine at 24 weeks post-protocol treatment compared to baseline, 24 weeks|Change in urinary type IV collagen, Proportional changes in geometric mean of urinary type IV collagen at 24 weeks post-protocol treatment compared to baseline, 24 weeks|Change in urinary alpha1-MG, Proportional changes in geometric mean of urinary alpha1-MG at 24 weeks post-protocol treatment compared to baseline, 24 weeks|Change in urinary beta2-MG, Proportional changes in geometric mean of urinary beta2-MG at 24 weeks post-protocol treatment compared to baseline, 24 weeks|Change in urinary NGAL, Proportional changes in geometric mean of urinary NGAL at 24 weeks post-protocol treatment compared to baseline, 24 weeks|Change in urinary NAG, Proportional changes in geometric mean of urinary NAG at 24 weeks post-protocol treatment compared to baseline, 24 weeks|Change in urinary L-FABP, Proportional changes in geometric mean of urinary L-FABP at 24 weeks post-protocol treatment compared to baseline, 24 weeks
|
